CIP2A is a target of bortezomib in human triple negative breast cancer cells

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Tseng, Ling Ming ^a,b   Liu, Chun Yu ^a,b   Chang, Kung Chi ^a,b   Chu, Pei Yi ^c   Shiau, Chung Wai ^b   Chen, Kuen Feng ^d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c ST MARTIN DE PORRES HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; ESTROGEN RECEPTOR; MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AUTOANTIGEN; BORONIC ACID DERIVATIVE; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROTECTION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOANTIGENS; BORONIC ACIDS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; MICE; MICE, NUDE; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; RECEPTORS, ESTROGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860130283     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3175     Document Type: Article

References (48)

1. Elias AD. Triple-Negative Breast Cancer: a short review. Am J Clin Oncol 2009, 33:637-645.
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948. 10.1056/NEJMra1001389, 21067385.
3. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008, 14:8010-8018. 10.1158/1078-0432.CCR-08-1208, 19088017.
4. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008, 14:1649-1657. 10.1158/1078-0432.CCR-07-2218, 18347166.
5. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006, 46:189-213. 10.1146/annurev.pharmtox.46.120604.141300, 16402903.
6. Orlowski RZ, Baldwin AS. NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002, 8:385-389. 10.1016/S1471-4914(02)02375-4, 12127724.
7. Suh KS, Goy A. Bortezomib in mantle cell lymphoma. Future Oncol 2008, 4:149-168. 10.2217/14796694.4.2.149, 18407730.
8. Cardoso F, Ross JS, Picart MJ, Sotiriou C, Durbecq V. Targeting the ubiquitin-proteasome pathway in breast cancer. Clin Breast Cancer 2004, 5:148-157. 10.3816/CBC.2004.n.020, 15245620.
9. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006, 5:665-675.
10. Orlowski RZ, Dees EC. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 2003, 5:1-7. 10.1186/bcr660, 154126, 12559038.
11. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 2007, 25:733-737. 10.1080/07357900701506573, 17952740.
12. Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006, 17:813-817. 10.1093/annonc/mdj131, 16403809.
13. Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer 2010, 10:465-470. 10.3816/CBC.2010.n.061, 21147690.
14. Schmid P, Kuhnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, Kümmel S, Van de Velde H, Regierer A, Possinger K. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 2008, 19:871-876. 10.1093/annonc/mdm569, 18209010.
15. Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, Baselga J. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 2008, 98:1500-1507. 10.1038/sj.bjc.6604347, 2391111, 18454159.
16. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996, 192:768-780. 10.1016/S0344-0338(96)80099-9, 8880878.
17. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008, 68:6698-6707. 10.1158/0008-5472.CAN-08-0257, 18701494.
18. Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY, Tokuda Y. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 2007, 98:1889-1892. 10.1111/j.1349-7006.2007.00622.x, 17892507.
19. Bielinski VA, Mumby MC. Functional analysis of the PP2A subfamily of protein phosphatases in regulating Drosophila S6 kinase. Exp Cell Res 2007, 313:3117-3126. 10.1016/j.yexcr.2007.05.008, 1991331, 17570358.
20. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008, 111:275-284. 10.1182/blood-2006-10-053884, 2200813, 17761520.
21. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009, 284:11121-11133. 2670117, 19261616.
22. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 2010, 52:88-95. 10.1016/j.jhep.2009.10.011, 19913321.
23. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8:355-368. 10.1016/j.ccr.2005.10.015, 16286244.
24. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008, 22:954-965.
25. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996, 271:11059-11062. 10.1074/jbc.271.19.11059, 8626647.
26. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010, 29:6257-6266. 10.1038/onc.2010.357, 20729919.
27. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011, 18:857-865. 10.1245/s10434-010-1313-8, 20842459.
28. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, Chan EK. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 2010, 10:694-699. 10.4161/cbt.10.7.12895, 3230513, 21068540.
29. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009, 101:793-805. 10.1093/jnci/djp103, 19470954.
30. Vaarala MH, Vaisanen MR, Ristimaki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010, 29:136. 10.1186/1756-9966-29-136, 2984408, 20964854.
31. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011, 33:290-298. 10.1111/j.1751-553X.2010.01288.x, 21219591.
32. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130:51-62. 10.1016/j.cell.2007.04.044, 17632056.
33. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009, 15:5092-5100. 10.1158/1078-0432.CCR-08-3283, 19671842.
34. Janicke RU. MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 2009, 117:219-221. 10.1007/s10549-008-0217-9, 18853248.
35. Janicke RU, Ng P, Sprengart ML, Porter AG. Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 1998, 273:15540-15545. 10.1074/jbc.273.25.15540, 9624143.
36. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998, 273:9357-9360. 10.1074/jbc.273.16.9357, 9545256.
37. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007, 18:116-121.
38. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004, 10:3371-3376. 10.1158/1078-0432.CCR-03-0508, 15161691.
39. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004, 22:115-119.
40. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008, 11:164-179. 10.1016/j.drup.2008.08.002, 18818117.
41. Chen KF, Yu HC, Liu CY, Chen HJ, Chen YC, Hou DR, Chen PJ, Cheng AL. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol Cancer Ther 2011, 10:892-901. 10.1158/1535-7163.MCT-10-0794, 21393428.
42. Huang CY, Wei CC, Chen KC, Chen HJ, Cheng AL, Chen KF. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Lett 2012, 317:9-15. 10.1016/j.canlet.2011.11.005, 22085493.
43. Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ, Liu YQ, Pu JX, Xiao WL, Sun HD, Zhou GB. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One 2011, 6:e20159. 10.1371/journal.pone.0020159, 3105001, 21655278.
44. Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, Kim KI, Kim KY, Kwon J, Yoon do Y, Moon EY, Yang Y. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett 2011, 585:755-760. 10.1016/j.febslet.2011.01.018, 21241697.
45. Xu P, Xu XL, Huang Q, Zhang ZH, Zhang YB. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med Oncol 2011,
46. Ren J, Li W, Yan L, Jiao W, Tian S, Li D, Tang Y, Gu G, Liu H, Xu Z. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. Br J Cancer 2011, 105:1905-1911. 10.1038/bjc.2011.492, 22075943.
47. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Butzow R, Ristimaki A. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011, 105:989-995. 10.1038/bjc.2011.346, 21897396.
48. Niemela M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernila P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012,